A new hard-particle model for anisotropic fluids

We report a new hard-particle model system consisting of hard cylinders, we have determined the geometrical conditions that let us know whether or not two given cylinders overlap. In addition we have carried out Monte Carlo simulations sampling the canonical ensemble on this system, the numerical results indicate that this system exhibits mesomorphic behaviour

Correlations in the Sine-Gordon Model with Finite Soliton Density

We study the sine-Gordon (SG) model at finite densities of the topological charge and small SG interaction constant, related to the one-dimensional Hubbard model near half-filling. Using the modified WKB approach, we find that the spectrum of the Gaussian fluctuations around the classical solution reproduces the results of the Bethe ansatz studies. The modification of the collective coordinate method allows us to write down the action, free from infra-red divergencies. The behaviour of the density-type correlation functions is non-trivial and we demonstrate the existence of leading and sub-leading asymptotes. A consistent definition of the charge-raising operator is discussed. The superconducting-type correlations are shown to decrease slowly at small soliton densities, while the spectral weight of right (left) moving fermions is spread over neighboring "4k_F" harmonics.Comment: 12 pages, 3 eps figures, REVTEX; a discussion of fermions is adde

Persistence Exponents and Scaling In Two Dimensional XY model and A Nematic Model

The persistence exponents associated with the T=0 quenching dynamics of the two dimensional XY model and a two dimensional uniaxial spin nematic model have been evaluated using a numerical simulation. The site persistence or the probability that the sign of a local spin component does not change starting from initial time t=0 up to certain time t, is found to decay as L(t)^-theta, (L(t) is the linear domain length scale), with theta =0.305 for the two dimensional XY model and 0.199 for the two dimensional uniaxial spin nematic model. We have also investigated the scaling (at the late time of phase ordering) associated with the correlated persistent sites in both models. The persistence correlation length was found to grow in same way as L(t).Comment: 8 figures, only three new references are included in this version. (ref. 18 and ref. 32

Topological transition in a two-dimensional model of liquid crystal

Simulations of nematic-isotropic transition of liquid crystals in two dimensions are performed using an O(2) vector model characterised by non linear nearest neighbour spin interaction governed by the fourth Legendre polynomial $P\_4$. The system is studied through standard Finite-Size Scaling and conformal rescaling of density profiles of correlation functions. A topological transition between a paramagnetic phase at high temperature and a critical phase at low temperature is observed. The low temperature limit is discussed in the spin wave approximation and confirms the numerical results

High-Temperature series for the RPn−1RP^{n-1} lattice spin model (generalized Maier-Saupe model of nematic liquid crystals) in two space dimensions and with general spin dimensionality n

High temperature series expansions of the spin-spin correlation functions of the RP^{n-1} spin model on the square lattice are computed through order beta^{8} for general spin dimensionality n. Tables are reported for the expansion coefficients of the energy per site, the susceptibility and the second correlation moment.Comment: 6 pages, revtex, IFUM 419/FT, 2 figures not include

Viscosities of the Gay-Berne nematic liquid crystal

We present molecular dynamics simulation measurements of the viscosities of the Gay-Berne phenomenological model of liquid crystals in the nematic and isotropic phases. The temperature dependence of the rotational and shear viscosities, including the nonmonotonic behavior of one shear viscosity are in good agreement with experimental data. The bulk viscosities are significantly larger than the shear viscosities, again in agreement with experiment.Comment: 11 pages, 4 Postscript figures, Revte

Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis.

IntroductionEffective treatments for hormone-receptor-positive (HR(+)) breast cancer (BC) following relapse/progression on nonsteroidal aromatase inhibitor (NSAI) therapy are needed. Initial Breast Cancer Trials of OraL EveROlimus-2 (BOLERO-2) trial data demonstrated that everolimus and exemestane significantly prolonged progression-free survival (PFS) versus placebo plus exemestane alone in this patient population.MethodsBOLERO-2 is a phase 3, double-blind, randomized, international trial comparing everolimus (10 mg/day) plus exemestane (25 mg/day) versus placebo plus exemestane in postmenopausal women with HR(+) advanced BC with recurrence/progression during or after NSAIs. The primary endpoint was PFS by local investigator review, and was confirmed by independent central radiology review. Overall survival, response rate, and clinical benefit rate were secondary endpoints.ResultsFinal study results with median 18-month follow-up show that median PFS remained significantly longer with everolimus plus exemestane versus placebo plus exemestane [investigator review: 7.8 versus 3.2 months, respectively; hazard ratio = 0.45 (95% confidence interval 0.38-0.54); log-rank P < 0.0001; central review: 11.0 versus 4.1 months, respectively; hazard ratio = 0.38 (95% confidence interval 0.31-0.48); log-rank P < 0.0001] in the overall population and in all prospectively defined subgroups, including patients with visceral metastases, [corrected] and irrespective of age. The incidence and severity of adverse events were consistent with those reported at the interim analysis and in other everolimus trials.ConclusionThe addition of everolimus to exemestane markedly prolonged PFS in patients with HR(+) advanced BC with disease recurrence/progression following prior NSAIs. These results further support the use of everolimus plus exemestane in this patient population. ClinicalTrials.gov #NCT00863655

Incommensurate ground state of double-layer quantum Hall systems

Double-layer quantum Hall systems possess interlayer phase coherence at sufficiently small layer separations, even without interlayer tunneling. When interlayer tunneling is present, application of a sufficiently strong in-plane magnetic field $B_\parallel > B_c$ drives a commensurate-incommensurate (CI) transition to an incommensurate soliton-lattice (SL) state. We calculate the Hartree-Fock ground-state energy of the SL state for all values of $B_\parallel$ within a gradient approximation, and use it to obtain the anisotropic SL stiffness, the Kosterlitz-Thouless melting temperature for the SL, and the SL magnetization. The in-plane differential magnetic susceptibility diverges as $(B_\parallel - B_c)^{-1}$ when the CI transition is approached from the SL state.Comment: 12 pages, 7 figures, to be published in Physical Review

Defect structures and torque on an elongated colloidal particle immersed in a liquid crystal host

Combining molecular dynamics and Monte Carlo simulation we study defect structures around an elongated colloidal particle embedded in a nematic liquid crystal host. By studying nematic ordering near the particle and the disclination core region we are able to examine the defect core structure and the difference between two simulation techniques. In addition, we also study the torque on a particle tilted with respect to the director, and modification of this torque when the particle is close to the cell wall

Approaches to discontinuing efalizumab: an open-label study of therapies for managing inflammatory recurrence

BACKGROUND: Efalizumab is a humanised recombinant monoclonal IgG1 antibody for the treatment of moderate-to-severe plaque psoriasis. When treatment discontinuation is necessary, however, some patients may experience inflammatory recurrence of the disease, which can progress to rebound if untreated. This analysis evaluated approaches for managing inflammatory recurrence after discontinuation of efalizumab. METHODS: An open-label, multicentre, investigational study was performed in 41 patients with moderate-to-severe plaque psoriasis who had recently completed clinical studies with efalizumab and had developed signs of inflammatory recurrence following abrupt cessation of treatment. Patients were assigned by the attending physicians to receive one of five standardised alternative systemic psoriasis treatment regimens for 12 weeks. Efficacy of the different therapy options was assessed using the physician's global assessment (PGA) of change over time. RESULTS: More favourable PGA responses were observed in patients changing to cyclosporin (PGA of 'good', 'excellent' or 'cleared': 7/10 patients, 70.0%) or methotrexate (9/20, 45.0%), compared with those receiving systemic corticosteroids (2/8, 25.0%), retinoids (0/1, 0.0%) or combined corticosteroids plus methotrexate (0/2, 0.0%). While the majority (77.8%) of patients showed inflammatory morphology at baseline, following 12 weeks of the alternative therapies the overall prevalence of inflammatory disease was decreased to 19.2%. CONCLUSION: Inflammatory recurrence after discontinuation of efalizumab therapy is a manageable event, with a number of therapies and approaches available to physicians, including short courses of cyclosporin or methotrexate